KalVista Pharmaceuticals, Ltd.

Pharma

Pipeline Programs↗

Distinct drugs in development (Preclinical–Phase 3)

Indications↗

Distinct diseases across all programs

Clinical Trials↗

All sponsored trials (all statuses)

Orange Book Patents

Across 1 drug with upcoming expirations

Pipeline

Pipeline Snapshot

By Phase

1 drugs in development

Phase 31

By Therapeutic Area

top 1

Rare Disease

1100%

R&D Momentum

18/100

Pipeline Velocity

0/100

Trial Completion Rate

89/100

Pipeline Concentration

100/100

Pipeline Freshness

63/100

Activity

Recent Activity

Last 14 days

Jul 14, 2026

Approved for marketing

Treatment of Angioedema Attacks in Adolescent and Adult Patients 12 Years and Older With HAE Type I or II With Sebetralstat

Jul 14, 2026

Available

Treatment of Angioedema Attacks in Pediatric (Ages 2-11) Post-Trial and Naive Patients With HAE With Sebetralstat

Earlier

Jul 3, 2025FDAEkterly — EKTERLY

Jun 24, 2024TrialOpen-Label Safety, PK, and Efficacy Trial of Sebetralstat (KVD900) in Pediatric Patients (Ages 2-11) With HAE Type I or II

Oct 24, 2022TrialPK Subtrial in Adolescent Patients With HAE Type I or II Participating in the KVD900-302 Trial

Oct 24, 2022TrialAn Open-label Extension Trial to Evaluate the Long-term Safety of KVD900 (Sebetralstat) for On-Demand Treatment of Angioedema Attacks in Adolescent and Adult Patients With Hereditary Angioedema (HAE)

Feb 22, 2022TrialA Phase III, Crossover Trial Evaluating the Efficacy and Safety of KVD900 (Sebetralstat) for On-Demand Treatment of Angioedema Attacks in Adolescent and Adult Patients With Hereditary Angioedema (HAE)

Sep 27, 2021TrialA Trial to Evaluate the Efficacy and Safety of Different Doses of KVD824 for Prophylactic Treatment of HAE Type I or II

4 more events

May 19, 2020TrialPhase 1 Crossover Study in Healthy Subjects to Evaluate the PK Profile of KVD824 Following Single and Multiple Doses of Modified Release (MR) Formulations

Jul 2, 2019TrialA Phase II, Cross-over Clinical Trial Evaluating the Efficacy and Safety of KVD900 (Sebetralstat) in the On-demand Treatment of Angioedema Attacks in Adult Subjects With Hereditary Angioedema Type I or II

Feb 12, 2019TrialA Single and Multiple Doses Safety, Tolerability, Pharmacokinetics and Food Effect Study of KVD824 in Healthy Volunteers

Feb 16, 2018TrialStudy of the Intravitreal Plasma Kallikrein Inhibitor, KVD001, in Subjects With Center-involving Diabetic Macular Edema (ciDME)

Details

Company Info

Company Overview

—

Mkt Cap

—

Revenue

—

Cash

Patent Expirations

3 patent groups across drugs · Source: FDA Orange Book

DrugExpires

Ekterly5 patentsNov 26, 2035 Ekterly2 patentsJun 23, 2037 EkterlyJan 26, 2039

Pipeline

Drug Pipeline

Indication

Preclinical

Phase 1

Phase 2

Phase 3

Approved

Rare Disease

Hereditary Angioedema

KVD900

Rare Disease

Hereditary Angioedema

KVD900Phase 3

Regulatory

Regulatory Timeline

20251 event

FDAJul 3

Ekterly — EKTERLY

Application NDA219301 (NDA)

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)